RxDoctor Payments Data

Robert Finkel, MD

Gastroenterology · Silver Spring, MDNPI 1780769364

Payments from drug & device makers

$1,678in general payments, 2019–2025

Across 81 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$793
  • Bristol Myers Squibb$176
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$112
  • Sanofi$103
  • Boston Scientific$101
  • Johnson & Johnson$94
  • plus $300 from 11 others

What the payments were for

  • Food & beverage$1,678100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,678 in reported general payments places this provider in the 35th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$242,643
Medicare patients
577
Services billed
5,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin15$32,589
Dexlansoprazole DrDexlansoprazole23$7,891
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates127$7,332
Famotidine125$2,946
SutabSod Sulf/Pot Chloride/Mag Sulf17$2,850
Omeprazole167$2,438
Pantoprazole Sodium76$2,052
Colesevelam Hcl11$2,047
Esomeprazole Magnesium33$1,738
Rabeprazole Sodium19$1,225
Azathioprine11$364
Dicyclomine Hcl17$222
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl15$189
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav16$168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$112$32,58915 claims
Braintree Laboratories, Inc.Sutab$14$2,85017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 455 gastroenterology providers in Maryland.

Other gastroenterology in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →